[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"parkinson39s-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:parkinson39s-disease":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,69,97,121,142,162,183],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100601094","phase-1-a-study-to-assess-safety-and-efficacy-of-surgical-implant-of-rndp-001-in-patients-with-idiopathic-parkinsons-disease-100601094",false,"NCT07106021","A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease","A Phase 1b\u002F2a Study Assessing the Safety and Efficacy of Intraputamenal Dopaminergic Stem Cell Transplants in Patients With Idiopathic Parkinson's Disease","Inclusion Criteria:\n\n* Diagnosis of idiopathic Parkinson's disease consistent with the Movement Disorders Society Clinical Criteria\n* Age 45 to 75\n* Medically stable to undergo a surgical procedure\n\nExclusion Criteria:\n\n* Known Parkinson's disease gene mutation or variant\n* Previous infusion therapy or surgery for Parkinson's disease\n* History of allergic reaction or intolerance to an immunotherapeutic agent\n* Contraindication to MRI\n* Clinically significant medical conditions likely to interfere with the surgical procedure or study assessments","ALL","45 Years","75 Years",{"count":20,"type":21},12,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This clinical trial is designed to test the safety and tolerability of the study intervention, RNDP-001, which will be implanted into the brain of study participants during a surgical procedure.",[28,29],"Idiopathic Parkinson´s Disease","Parkinson's Disease",[31],"RNDP-001","RECRUITING","2026-01-22",{"date":35,"type":36},"2026-01-23","ACTUAL",{"date":38,"type":36},"2025-07-17",{"date":40,"type":21},"2031-06",{"name":42,"class":43},"Kenai Therapeutics","INDUSTRY",3,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100598971","home-use-study-of-targeted-mechanical-stimulation-for-tremor-relief-100598971","NCT07078422","Home Use Study of Targeted Mechanical Stimulation for Tremor Relief","Inclusion Criteria - Alpha and Beta Phase B1\n\n* Age 18 years or older, able to comply with all study procedures and capable of providing informed consent.\n* Mentally competent to understand and able to perform written, informed consent to participate in the study\n* A diagnosis of either ET or PD as determined by clinical history\n* Moderate to severe upper limb tremor\n\nExclusion Criteria - Alpha and Beta Phase B1\n\n* Pregnant women\n* Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at stimulation site\n* History of psoriasis, eczema or atopic dermatitis at the stimulation site\n* History of peripheral neuropathy in the upper limbs, including carpal tunnel syndrome and diabetic neuropathy\n* Participant unable to communicate with sponsor\u002Finvestigator and staff\n* Any other medical conditions or physical or mental impairments that in the sponsor\u002Finvestigator's opinion would render the subject unsuitable as a candidate for the study.\n\nInclusion Criteria - Beta Phase B2\n\n* Age 18 years or older, able to comply with all study procedures and capable of providing informed consent\n* Mentally competent to understand and able to perform written, informed consent to participate in the study\n* For ET subjects, a diagnosis of essential tremor defined as definite or probable ET based on TRIG criteria\n* For PD subjects, a diagnosis of Parkinson's disease by a Movement Disorder Specialist\n* For ET subjects, at least one hand exhibiting tremor \\> 2 as assessed by the Essential Tremor Rating Assessment Scale (TETRAS) finger to nose task, duck wing task, OR Archimedes Spiral completed during the Screening visit\n* For PD subjects, a score \\> 2 on at least one of MDS-UPDRS items 3.15, 3.16 or 3.17 At the Screening Visit, a score of \\> 3 on one of the following subject-assessed items of the Bain \\& Findley Activities of Daily Living Scale (BF-ADL): Use a spoon to drink soup, Hold a cup of tea, Do up buttons, Do up a zipper, Write a letter\n* Stable medications for at least 30 days prior to enrollment and the ability to maintain tremor medications throughout the duration of study participation\n* For PD subjects, able to participate in visits in a practically defined OFF state (withdrawal from all tremor medication for 12 hours prior to study visits)\n* A wrist circumference of 6.0 - 8.1 inches\n\nExclusion Criteria - Beta Phase B2\n\n* Pregnant women\n* Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at stimulation site\n* History of psoriasis, eczema or atopic dermatitis at the stimulation site\n* History of peripheral neuropathy in the upper limbs, including carpal tunnel syndrome and -diabetic neuropathy\n* Participant unable to communicate with sponsor\u002Finvestigator and staff\n* Any other medical conditions or physical or mental impairments that in the sponsor\u002Finvestigator's opinion would render the subject unsuitable as a candidate for the study","18 Years",{"count":53,"type":21},80,[55],"NA","Subjects will receive prototype devices to be used for participation. The study comprises three phases:\n\n1. Alpha phase: Two remote study visits and an in-home period to gather device usability data on the alpha system. The at home period for this phase will be 2 weeks. This phase will be used to confirm that the device and labeling are suitable for in-home use.\n2. Beta Phase B1: Beta Phase B1 will be conducted using the beta devices for two in-person or remote, 60 to 90-minute, visits. This phase will be used to assess design changes between alpha and beta versions.\n3. Beta Phase B2: Seven remote visits and in-home usage to gather usability and efficacy data on the beta system in-home. Beta Phase B2 will be conducted using the beta devices for 12 weeks. This phase will be used to assess design changes between alpha and beta versions.",[58,29],"Essential Tremor","2025-11-19",{"date":61,"type":36},"2025-11-24",{"date":63,"type":36},"2025-01-01",{"date":65,"type":21},"2026-06",{"name":67,"class":43},"Encora, Inc.",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":68},"100601814","eeg-measurements-to-capture-dbs-induced-electric-potentials-100601814","NCT07115394","EEG Measurements to Capture DBS-induced Electric Potentials","Inclusion Criteria:\n\n* Provision of written informed consent by the patient\n* Age 35 - 85\n* patient groups: Parkinson's disease, essential tremor, dystonia\n* \\>3 months after surgery for DBS\n\nExclusion Criteria:\n\nnone.","35 Years","85 Years",{"count":78,"type":21},20,"OBSERVATIONAL","To measure the electric fields induced by DBS (deep brain stimulation) on the scalp and to improve electric field simulations, the investigators will measure EEG (electroencephalography) measurements with high sampling rates (\\>100 kHz). The investigators hypothesize that we can improve electric field simulations of DBS by validating and calibrating the simulations based on EEG measurements at high sampling rates (\\>100 kHz).",[82,29],"Deep Brain Stimulation",[84,85,86],"deep brain stimulation","EEG","electric potential","2025-08-17",{"date":89,"type":36},"2025-08-21",{"date":91,"type":36},"2025-07-11",{"date":93,"type":21},"2026-12-31",{"name":95,"class":96},"Universitätsklinikum Hamburg-Eppendorf","OTHER",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":68},"100600644","early-phase-1-evaluation-of-gm101-injection-in-patients-with-parkinsons-disease-100600644","NCT07100171","Evaluation of GM101 Injection in Patients With Parkinson's Disease","A Single-Center, Open-Label, Single-Arm Exploratory Study Evaluating GM101 Injection in Patients With Mid-to-Late Stage Parkinson's Disease","Inclusion Criteria:\n\n1. Clinically diagnosed patients with primary Parkinson's Disease \\[in accordance with the \"Diagnostic Criteria for Parkinson's Disease in China\" released in 2016\\];\n2. Participants must be able to comprehend (fully understand the details of the clinical trial and the potential risks and benefits of the study) and voluntarily sign the informed consent form. When participants are unable to read, the informed consent form and other written materials may be read by a legal representative or an impartial witness, who will also witness the consent process;\n3. Age between 40 and 70 years old, inclusive, regardless of gender;\n4. Body weight between 40 kg and 110 kg, and Body Mass Index (BMI) between 18 kg\u002Fm² and 34 kg\u002Fm²;\n5. A history of Parkinson's Disease for \\>= 5 years;\n6. Able to undergo surgical anesthesia, suitable for neurosurgical procedures under anesthesia, and capable of undergoing CT\u002FMRI examinations;\n7. Hoehn-Yahr stage (Appendix IV Hoehn-Yahr Staging) at screening in the \"off\" state is 4-5 (including borderline values);\n8. MDS-Unified Parkinson's Disease Rating Scale Part III Motor Examination (MDS-UPDRS-III) score in the \"off\" state \\>= 30; and a positive levodopa challenge test (improvement in UPDRS-III score from \"off\" to \"on\" state \\>30%);\n9. Patients whose PD symptoms cannot be effectively controlled or who experience intolerable adverse drug reactions despite treatment with medications recommended by the \"Chinese Guidelines for the Treatment of Parkinson's Disease (4th Edition)-2020\";\n10. Receiving a stable dose of anti-Parkinson's medication for at least 4 weeks prior to administration;\n11. Acceptable laboratory values during the screening period and prior to administration (Day 0): a) Hemoglobin \\>= 100 g\u002FL; b) Platelets \\>= 100×10\\^9\u002FL; c) Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\\u003C= 1.5 times the upper limit of normal; d) Total bilirubin \\\u003C= 1.5 times the upper limit of normal; e) Serum creatinine (Cr) \\\u003C= 1.5 times the upper limit of normal;\n12. Participants agree not to receive any other therapeutic intervention studies during the main study phase;\n13. Participants agree not to participate in any other clinical studies during the study period;\n14. Participants agree not to receive any other vaccines within 30 days after administration;\n15. Participants must have the ability to live independently or the ability to clearly delegate relevant caregivers, with good compliance, and be able to attend regular follow-ups. During follow-up, participants must accurately complete the PD patient diary, and family members, guardians, or caregivers may assist in filling out the patient diary;\n16. Participants must have a pre-existing neutralizing AAV8 antibody titer \\\u003C= 1:90 as determined by testing;\n17. Based on the judgment of the Principal Investigator (PI), cancer-related screening will be conducted for patients who meet the inclusion criteria.\n\nExclusion Criteria:\n\n1. Patients with atypical parkinsonian syndromes (Parkinson-plus syndromes, secondary Parkinson's syndrome, or hereditary Parkinson's syndrome).\n2. Patients who have previously undergone pallidotomy, deep brain stimulation (DBS) surgery, striatal\u002Fextrapyramidal system surgery, stereotactic brain surgery, or other cerebral surgeries that might affect the observation of this trial's outcomes; or those who have undergone other surgeries deemed by investigators to interfere with study participation.\n3. Patients with intracranial lesions revealed by previous CT\u002FMRI scans, such as cerebral trauma, cerebrovascular malformations, hydrocephalus, brain tumors, or striatal\u002Fother brain region abnormalities that significantly increase surgical risks.\n4. Patients with history of the following cardiovascular\u002Fcerebrovascular diseases: 1)Severe heart failure, unstable angina, or myocardial infarction; 2)Severe arrhythmias including but not limited to II\u002FIII-degree atrioventricular block or prolonged QT interval; 3)Long QT syndrome; 4)Cardiovascular surgery history; 5)History of stroke or transient ischemic attack (TIA) within 3 months, deemed ineligible by investigators; 6)Subarachnoid hemorrhage history; 7)Major vascular diseases considered ineligible by investigators.\n5. Patients with history of malignant tumors.\n6. Patients who have received cell therapy.\n7. Patients who have received gene therapy.\n8. Patients with active disseminated intravascular coagulation or significant bleeding tendency within 3 months prior to consent, or those unable to discontinue antiplatelet\u002Fanticoagulant medications \\>= 7 days pre-operation, or whose coagulation function hasn't normalized \\>= 10 days after stopping antiplatelet medications.\n9. Patients who received prolonged \\>= 14 days) high-dose systemic corticosteroids (prednisone \\>= 20 mg\u002Fday or equivalent) or immunosuppressants within 3 months prior to consent (topical use excluded).\n\n10,Patients with psychiatric disorders deemed ineligible by investigators; or those with suicidal ideation\u002Fattempts (including actual attempts, interrupted attempts, or aborted attempts) within the past year or currently.\n\n11.Patients who received botulinum toxin treatment within 6 months prior to consent.\n\n12.Patients with active epilepsy or currently using antiepileptic drugs. 13.Patients with dementia or severe cognitive impairment history; or those showing significant dementia\u002Fcognitive dysfunction during screening; MDS-UPDRS Part 1.1 cognitive impairment score \\>3; dementia affecting compliance, diary accuracy, and\u002For informed consent capability.\n\n14\\. Individuals with severe depression (Hamilton Depression Rating Scale \\[HAM-D17\\] score \\>= 24) or severe anxiety (Hamilton Anxiety Rating Scale \\[HAMA\\] score \\>= 29) during screening.\n\n15\\. Individuals with the following clinically significant abnormalities during screening: 1) Abnormal coagulation function (prothrombin time \\>= 1.5 times the upper limit of normal, activated partial thromboplastin time \\>= 1.5 times the upper limit of normal); 2) Clinically significant immunological abnormalities, deemed unsuitable for participation by the investigator; 3) Poorly controlled hypertension (defined as blood pressure remaining above 160\u002F100 mm Hg despite antihypertensive treatment) and severe orthostatic hypotension; 4) Poorly controlled diabetes (glycated hemoglobin \\> 9.0%, or fasting plasma glucose \\[FPG\\] \\>= 11.1 mmol\u002FL).\n\n16\\. Individuals with surgical contraindications (e.g., prior cochlear implant, pacemaker, defibrillator, stereotactic neurosurgery, or prior implantation of unilateral or bilateral similar devices) or those who have undergone other surgeries within the past six months that the investigator believes may affect the trial, or those with allergies (e.g., to contrast agents) preventing MRI, or other neurosurgical contraindications.\n\n17\\. Individuals with other severe systemic diseases, such as cor pulmonale, severe chronic obstructive pulmonary disease (COPD) (FEV1% \\\u003C 50%), etc.\n\n18\\. Individuals with any of the following conditions: positive human immunodeficiency virus (HIV) antibody; positive syphilis antibody; positive hepatitis C virus (HCV) antibody with detectable HCV RNA; positive hepatitis B virus surface antigen with HBV DNA copy number above the normal limit; active tuberculosis; or other active infections deemed by the investigator to potentially affect participation or study outcomes.\n\n19\\. Individuals with alcohol addiction, positive drug abuse screening, or a history of drug dependence.\n\n20\\. Individuals with contraindications or allergies to any components of the drugs used in the study (e.g., tacrolimus, levodopa) or to similar drugs or other macrolide drugs, or those with a history of allergies (e.g., to two or more drugs or foods).\n\n21\\. Women of childbearing potential or breastfeeding women who have not undergone sterilization, are not postmenopausal, or are unwilling to use medically approved effective contraception for two years after receiving the study drug, and men who have not undergone sterilization or are unwilling to use medically approved effective contraception for two years after receiving the study drug.\n\n22\\. Individuals who have received electroconvulsive therapy within 30 days prior to dosing.\n\n23\\. Individuals currently participating in other clinical trials or those who have participated in other clinical studies and received interventional treatment within three months prior to dosing.\n\n24\\. Individuals deemed by the investigator to have poor compliance. 25. Patients currently receiving treatment such as apomorphine or levodopa infusion therapy (Duodopa®).\n\n26\\. Individuals with severe movement disorders in both medicated and unmedicated states.\n\n27\\. Individuals with major illnesses or any other conditions deemed by the investigator to jeopardize the safety of the participant or affect the investigator's assessments.","40 Years","70 Years",{"count":107,"type":21},10,[109],"EARLY_PHASE1","The objective of this study is to assess the safety of GM101 in participants with Parkinson's disease (PD)",[29],"2025-07-27",{"date":114,"type":36},"2025-08-03",{"date":116,"type":36},"2025-05-29",{"date":118,"type":21},"2030-02-17",{"name":120,"class":43},"Genemagic Biosciences Co., Ltd",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":104,"maxAge":18,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":140,"locationsCount":4},"100589201","clinical-trial-of-vildagliptin-in-early-parkinsons-disease-100589201","NCT06951334","Clinical Trial of Vildagliptin in Early Parkinson's Disease","VERY-PD","Inclusion Criteria:\n\n* 1: Patients aged 40 to 75 years who were diagnosed with Parkinson's disease according to the UK Brain Bank criteria within the past three years.\n\n  2: Participants must have received an optimized and stable dopaminergic medication regimen (dopamine agonists, levodopa, or monoamine oxidase B \\[MAOB\\] inhibitors, or combinations of these medications) determined by the study site investigators for at least one month prior to the baseline initiation of the trial drug, with the expectation that the participants will be able to continue this regimen for at least six months.\n\n  3: Sign the informed consent form\n\nExclusion Criteria:\n\n* 1: The key exclusion criterion is a score of at least 3 on the Hoehn and Yahr scale (ranging from 1 to 5, with higher scores indicating more severe disability), which indicates that Parkinson's disease has led to at least mild to moderate bilateral motor involvement due to some postural instability.\n\n  2: Presence of motor fluctuations or motor complications (or both).\n\n  3: The presence of severe psychiatric disorders, such as severe (treatment-resistant) anxiety, depression, or schizophrenia, that cannot be effectively controlled by medication.\n\n  4: Atypical or secondary Parkinsonism\n\n  5: A score of 18 or lower on the Montreal Cognitive Assessment (MoCA) (range: 0 to 30, with a score of 26 or higher indicating normal cognitive function), indicating at least mild cognitive impairment.\n\n  6: Diabetes mellitus (Type 1 and Type 2), as well as prior treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like peptide-1 (GLP-1) receptor agonists.\n\n  7: Individuals with severe renal impairment (creatinine clearance \\\u003C30 ml\u002Fmin), active liver disease, history of drug or alcohol abuse, idiopathic pancreatitis, chronic pancreatitis, or a history of pancreatectomy.\n\n  8: Individuals with a body mass index (weight in kilograms divided by the square of height in meters) less than 18.5, or those with a weight change exceeding 5 kilograms within the 3 months prior to screening.\n\n  9: Currently participating in other relevant clinical trials involving pharmacological or surgical treatments.\n\n  10: Other situations where the investigator believes that the subject is unable to participate in or cooperate with the entire assessment process of the clinical trial.",{"count":129,"type":21},66,[55],"Investigating the efficacy of Vildagliptin in delaying the progression of Parkinson's disease.",[29],"NOT_YET_RECRUITING","2025-04-26",{"date":136,"type":36},"2025-04-30",{"date":138,"type":21},"2025-06-01",{"date":93,"type":21},{"name":141,"class":96},"First Affiliated Hospital, Sun Yat-Sen University",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":104,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":4},"100581369","the-relationship-between-homocysteine-and-manifestation-of-parkinsons-disease-patients-100581369","NCT06849414","The Relationship Between Homocysteine and Manifestation of Parkinson's Disease Patients","The Relationship Between Blood Homocysteine Level and Motor and Cognitive Manifestation of Parkinson's Disease Patients","Inclusion Criteria:\n\n* 1-Inpatients or outpatients from the clinic of movement disorders of neuropsychiatry hospital of Assiut university 2-The age group of the patients is those above 40 years\n\nExclusion Criteria:\n\n* 1-Secondary parkinsonism associated with specific causes such as infections, medication-induced, poisoning, cerebral arteriosclerosis, and trauma 2-Parkinsonism accompanied by other neurodegenerative disease ( specifically multiple syste atrophy, progressive supranuclear palsy, and dementia with Lewy bodies).\n\n  3-Presence of significant memory or cognitive decline preceding the onset of PD symptoms, as reported by both the patient and\u002For family members 4-Significant intracranial lesions detected on brain MRI 5-Unable to cooperate in completing the clinical scale assessment and blood sample collection.\n\n  6-Recent or current use of medications such as antiepileptic drugs and certain chemotherapy drugs that can impact blood Hcy levels or the presence of thyroid dysfunction or renal insufficiency that affects Hcy metabolism.",{"count":150,"type":21},44,"* The aim of the current study is to investigate the association between blood homocysteine level and motor as well as cognitive manifestation of PD patients in Assiut governorate.\n* Secondary goal is to investigate the association between levels of serum ferritin, iron as well as acute phase proteins (fibrinogen, D-dimer, CRP) and manifestation of PD.",[29],"2025-02-24",{"date":155,"type":36},"2025-02-27",{"date":157,"type":21},"2025-06",{"date":159,"type":21},"2026-07",{"name":161,"class":96},"Assiut University",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":168,"maxAge":105,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":174,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":181,"locationsCount":68},"100581308","a-single-blind-randomized-controlled-clinical-study-of-flash-stimulation-therapy-in-parkinsons-disease-100581308","NCT06848621","A Single-blind, Randomized, Controlled Clinical Study of Flash Stimulation Therapy in Parkinson's Disease","Inclusion Criteria:\n\n1. PD patients who meet the diagnostic criteria of the International Movement Disorders Association (MDS), between the ages of 50 and 70 years, the course of disease ≤5 years, and the Hoehn \\& Yahr stage ≤3;\n2. Anti-PD drugs were taken regularly for at least one month before screening, and symptoms were stable;\n3. The fixed bedtime in the past month is between 9:00 p.m. and 1:00 a.m., and the total sleep time is ≥6 hours;\n4. Have the ability to understand and voluntarily sign informed consent;\n5. Have good compliance and are willing to complete all follow-up required by this program.\n\nExclusion Criteria:\n\n1. Secondary insomnia: including sleep disorders (restless leg syndrome, periodic limb movement disorder, sleep-related breathing disorders, etc.), physical diseases, mental disorders, psychoactive substance abuse;\n2. suffering from photosensitive dermatitis, epilepsy and other diseases that are not suitable for flash stimulation;\n3. Alcohol, coffee, or drug abusers in the past 6 months;\n4. Mental illness: such as anxiety, depression, schizophrenia and post-traumatic stress disorder caused by insomnia;\n5. Used drugs or health products that regulate sleep function or affect sleep within 14 days before enrollment or less than 5 drug half-lives;\n6. Taking drugs that may impair cognitive ability, such as anticholinergic drugs, memory enhancing drugs, etc., within 7 days before enrollment;\n7. the subject is unable to complete the test or follow-up;\n8. suffering from other neurodegenerative diseases;\n9. There are endoplants in the body that cannot be examined by MRI;\n10. Inability to lie flat;\n11. Other situations in which the researcher considers it inappropriate to participate in the study.","50 Years",{"count":170,"type":21},48,[55],"The aim of this study was to evaluate the effect of flash stimulation therapy on the function of the cerebral glymphatic system and efficacy of improving symptoms in PD patients.",[29],[175],"Parkinson's disease","2025-02-21",{"date":155,"type":36},{"date":179,"type":21},"2025-03-01",{"date":93,"type":21},{"name":182,"class":96},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":191,"maxAge":18,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":195,"conditions":196,"keywords":197,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":68},"100570031","study-of-the-test-retest-reliability-of-the-neuropsychiatric-fluctuations-scale-in-parkinson39s-disease-100570031","NCT06701955","Study of the Test-retest Reliability of the Neuropsychiatric Fluctuations Scale in Parkinson's Disease","Study of the Test-retest Reliability of the Neuropsychiatric Fluctuations Scale (EFN)","EFN-RETEST","Inclusion Criteria:\n\nAge \\> 30 and ≤ 75 years\n\n* Idiopathic Parkinson's disease (according to the criteria of the Movement Disorders Society)\n* Presence of motor fluctuations described by the patient, their relatives, or identified by the clinician\n* Stability of antiparkinsonian treatment for at least one month\n* Mastery of the French language\n* Able to give consent.\n* Affiliated to the social security system\n\nExclusion Criteria:\n\nParkinsonian syndrome other than idiopathic Parkinson's disease\n\n* Dementia (MoCa \\\u003C 23)\n* No antiparkinsonian treatment or treatment modified for less than one month\n* Persons referred to in Articles L1121-5 to L1121-8 of the CSP (corresponds to all protected persons: pregnant women, parturients, breastfeeding mothers, persons deprived of liberty by judicial or administrative decision, persons receiving psychiatric care under Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8, persons admitted to a health or social establishment for purposes other than research, minors, persons subject to a legal protection measure or unable to express their consent))\n* Subject in a period of exclusion from another interventional study.","30 Years",{"count":193,"type":21},100,[55],"This study focuses on neuropsychiatric fluctuations (NPF) in Parkinson's disease. Due to the lack of specific assessment tools, we developed the Neuropsychological Fluctuations Scale (NFS), a 20-item questionnaire. Recent studies have confirmed its reliability, sensitivity, and validity. To finalize its validation, assessing its test-retest reliability is an essential next step.",[29],[198,199,200,201],"neuropsychiatric fluctuations","scale validation","psychometric caracteristics","non-motor symptoms","2025-01-17",{"date":204,"type":36},"2025-01-20",{"date":206,"type":21},"2025-02-01",{"date":208,"type":21},"2027-03-01",{"name":210,"class":96},"University Hospital, Grenoble"]